PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,302,649
|
miro gtpase domain regul assembl mitochondri motor adaptor complex mitochondri transport reli motor adaptor complex contain miro mitochondri outer membran protein two gtpase domain trak kinesin dynein use peroxisom direct miro quantifi abil gtpase mutat influenc peroxisom recruit complex compon miro whose n gtpase lock gdp state recruit trak kinesin p peroxisom wherea gtp state similar express mirogap vope dislodg trak mitochondria miro c gtpase mutat littl influenc complex recruit although miro thought support mitochondri motil peroxisom direct miro recruit complex compon regardless state gtpase domain neuron express peroxisom miro gtp state form n gtpase mark increas peroxisom transport growth cone wherea gdp state caus retent soma thus n gtpase domain miro critic regul miro interact compon motor adaptor complex therebi regul mitochondri motil
|
D024101;D016547
|
T123;T126;T116
|
36,302,590
|
elimin dispar cardiovascular diseas black women jacc review topic week black women disproportion affect cardiovascular diseas excess burden cardiovascular morbid mortal addit racial structur unit state shape cardiovascular diseas research health care deliveri black women given indisput evid dispar health care deliveri research cardiovascular outcom urgent need develop implement effect sustain solut advanc cardiovascular health equiti black women consid ethnic divers region origin accultur innov cultur tailor strategi consid differenti impact social determin health uniqu challeng shape health seek behavior implement patient center framework involv collabor among clinician health care system profession societi govern agenc requir improv cardiovascular outcom black women time achiev health equiti black women
|
D002318;D000069576
|
T047;T080
|
36,302,588
|
relationship circul veget omega prognosi patient heart failur urgent need cost effect strategi promot qualiti life patient heart failur hf sever studi report benefit hf prognosi marin omega fatti acid plant base dietari pattern
|
D015525;D006333
|
T123;T121;T109;T047;T046
|
36,302,586
|
biomark base predict recurr ischem event patient acut coronari syndrom patient acut coronari syndrom ac residu variabl risk recurr ischem event
|
D054058;D009203;D062645
|
T061;T047
|
36,302,584
|
cardiovascular effect canagliflozin relat renal function albuminuria peopl type diabet mellitus tdm elev cardiovascular cv risk includ hospit heart failur hhf canagliflozin reduc cv kidney event patient tdm high cv risk nephropathi canva canagliflozin cardiovascular assess studi program credenc canagliflozin renal event diabet establish nephropathi clinic evalu trial
|
D002318;D003924;D003928;D006333;D000077203
|
T121;T047;T046;T109
|
36,302,583
|
healthcar provid attitud belief barrier pulmonari rehabilit patient chronic obstruct pulmonari diseas saudi arabia cross section studi assess attitud healthcar provid hcps toward deliv pulmonari rehabilit pr patient chronic obstruct pulmonari diseas copd identifi factor barrier might influenc referr
|
D011788;D029424
|
T078;T047
|
36,302,582
|
transit care youth onset type type diabet scope review protocol use socio ecolog model framework transit paediatr adult diabet care youth onset diabet type diabet mellitus tdm type diabet mellitus tdm associ worsen glycaem control miss clinic visit decreas medic adher emerg cardiometabol complic socio ecolog challeng influenc transit adult diabet care may distinct tdm tdm goal scope review map state literatur transit care tdm compar tdm identifi main sourc type evid avail object identifi factor within socio ecolog framework individu relationship communiti societ associ transit adult care tdm compar tdm identifi knowledg gap relat transit adult care
|
D003924;D003922;D000069341
|
T047;T058
|
36,302,581
|
physic mental health problem chines front line healthcar worker covid rescu mission qualit studi explor physic mental health problem front line healthcar worker fight covid across three phase epidem rescu mission china
|
D000086382;D058872
|
T047;T067
|
36,302,580
|
disrupt procur medic abort medicin covid scope review scope review aim systemat search retriev map extent characterist avail literatur evidenc disrupt medic abort medicin procur caus covid outbreak
|
D000086382
|
T047;T067
|
36,302,579
|
covid pandem chang children physic activ rural us communiti mix method studi examin differ rural communiti children moder vigor physic activ mvpa particip school activ fall fall explor enact pa opportun modif post initi covid disrupt
|
D000086382
|
T047;T067
|
36,302,578
|
antibiot prescript use digit decis support system regist base studi patient hard heal ulcer sweden investig differ antibiot prescript patient hard heal ulcer assess use digit decis support system ddss compar assess without use ddss aim examin predictor antibiot prescript
|
D014456;D000900
|
T121;T046;T195
|
36,302,577
|
scope review identifi strategi intervent improv interprofession collabor integr primari care identifi strategi intervent use improv interprofession collabor integr ipci primari care
|
D003695;D011320
|
T058;T093
|
36,302,576
|
studi preval basic epidemiolog concept gain recognit covid pandem preval measur occurr health condit exposur factor relat health experi covid new diseas caus sar cov highlight import preval studi issu report methodolog tradit neglect
|
D000086382
|
T047;T067
|
36,302,575
|
perform evalu hipe point care test urin dipstick analys cross section studi advanc mobil technolog smartphon base point care test poct urinalysi hold great potenti diseas screen health manag clinician individu user purpos studi evalu analyt perform hipe poct urin dipstick analys
|
D000419;D016482
|
T033;T059
|
36,302,574
|
calibr network meta analysi diabet trial sodium glucos cotransport inhibitor glucagon like peptid receptor analogu dipeptidyl peptidas inhibitor repres routin popul systemat review protocol particip randomis control trial trial general younger healthier mani individu encount clinic practic consequ applic trial find often uncertain address result trial calibr repres data sourc network meta analysi use novel approach allow inclus trial whether individu level particip data ipd avail calibr trial three drug class sodium glucos cotransport sglt inhibitor glucagon like peptid glp receptor analogu dipeptidyl peptidas dpp inhibitor scottish diabet regist
|
D003924;D054873;D000077203
|
T121;T047;T109
|
36,302,573
|
general practic perspect use telehealth covid pandem australia use action research approach qualit studi telehealth emerg viabl safe mode care deliveri australia covid pandem howev electron general practic data reveal differ uptak consult mode hypothesis may due potenti barrier impact qualiti care aim identifi benefit barrier telehealth use general practic use action research approach involv general practition gps general practic stakehold
|
D000086382;D017216;D058006
|
T047;T058;T091;T067
|
36,302,572
|
determin earli initi breast feed among mother children age less month ethiopia communiti base cross section studi studi aim assess preval earli initi breast feed eibf associ factor among mother children less year age ethiopia
|
D001942;D009035
|
T055;T092;T040;T099;T058
|
36,302,571
|
co design health literaci inform intervent base need assess studi chronic obstruct pulmonari diseas develop co design health literaci hl inform intervent peopl chronic obstruct pulmonari diseas copd enabl find understand rememb use communic health inform need promot maintain good health
|
D057220;D029424
|
T047;T041
|
36,302,570
|
pirfenidon prevent radiat induc lung injuri patient local advanc oesophag squamous cell carcinoma protocol randomis control trial radiat induc lung injuri rili one clinic challeng toxic dose limit factor andor thorac radiat therapi oesophag squamous cell carcinoma escc limit effect protect drug rili main strategi reduc injuri strict adher dose volum restrict normal lung rili manifest acut radiat pneumon cellular injuri cytokin releas cytokin recruit inflammatori infiltr subsequ chronic radiat pulmonari fibrosi pirfenidon inhibit product inflammatori cytokin scaveng free radic reduc hydroxyprolin collagen format henc pirfenidon might promis drug rili prevent studi aim evalu efficaci safeti pirfenidon prevent rili patient local advanc escc receiv chemoradiotherapi
|
D004938;D000077277;D055370;D011832
|
T047;T191;T037
|
36,302,569
|
arch adult recipi cochlear implant health social long term outcom state specif nation popul base retrospect cohort studi protocol major adult sever profound hear loss poor speech percept outcom hear aid benefit receiv cochlear implant long term health social benefit implant recipi yet explor object arch research provid better understand health social factor play role live adult cochlear implant year procedur
|
D003054;D019929;D006310
|
T061;T074
|
36,302,567
|
safeti efficaci belimumab patient lupus nephriti open label extens bliss ln studi bliss ln studi belimumab improv kidney outcom adult patient activ lupus nephriti week open label extens bliss ln assess belimumab safeti efficaci
|
D008181;D008180
|
T047
|
36,302,566
|
longitudin evalu donor deriv cellfre dna pediatr kidney transplant donor deriv cellfre dna cfdna less invas marker allograft injuri compar kidney biopsi howev donor deriv cfdna yet extens test children test may differ characterist
|
D016030;D000073888
|
T061;T123;T114
|
36,302,564
|
comparison pd l tumor cell express c sp ihc assay across multipl tumor type multipl pd l immunohistochemistri ihc assay includ dako c dako ventana sp pd l ihc assay approv food drug administr companion diagnost cdx various antiprogram death antiprogram death ligand pd l base cancer immunotherapi present c sp analysi tumor specimen encount routin clinic practic
|
D002289;D008175
|
T191
|
36,302,563
|
hkm mutat suitabl target immunotherapi hla patient diffus midlin glioma diffus midlin glioma lead caus solid cancer relat death children limit treatment option major tumor carri point mutat histon variant h creat potenti hla bind epitop hkm isol hkm specif cell receptor tcr transgen mice express divers human tcr repertoir despit high function avid hkm specif cell abl achiev recognit cell natur express hkm mutat even overexpress transgen similar result obtain cell express publish tcr h epitop crisprca edit use exclud interfer endogen tcrs donor cell overal data provid strong evid hkm mutat suitabl target cancer immunotherapi like due insuffici epitop process andor amount recogn hla restrict cd cell
|
D005910;D015789
|
T129;T191;T116
|
36,302,562
|
first human studi ox ivuxolimab bb utomilumab agonist antibodi combin patient advanc solid tumor ivuxolimab pf utomilumab pf human agonist igg monoclon antibodi ox bb respect first human multicent open label phase dose escalationdos expans studi explor safeti toler pharmacokinet pharmacodynam antitumor activ ivuxolimabutomilumab patient advanc solid tumor
|
D009369;D000971
|
T061;T191
|
36,302,561
|
engag attrit ehealth tool remot monitor chronic arthriti systemat review meta analysi although ehealth tool potenti use remot diseas monitor barrier includ concern low engag high attrit aim summaris evid patient engag attrit ehealth tool remot monitor diseas activityimpact chronic arthriti
|
D017216;D063731;D001168
|
T058;T170;T047
|
36,302,559
|
compar analysi terrain vehicl motorcycl automobil relat trauma rural border communiti usa widespread use terrain vehicl atv usa work relat recreat activ studi aim determin differ injuri sever glasgow coma scale length stay atv relat injuri injuri sustain motorcycl moto automobil auto
|
D015541;D014947
|
T073;T037
|
36,302,557
|
identifi understand diseas burden patient inflammatori bowel diseas physician tend focus biomed target littl known issu import patient aim identifi critic concept impact patient inflammatori bowel diseas ibd
|
D003093;D003424;D015212
|
T047
|
36,302,555
|
usp substrat identifi proteom analysi reveal specif usp deubiquityl enzym dub remov ubiquitin chain protein regul protein stabil function usp one extens studi dub sinc usp sever well known substrat import cancer progress mdm n myc pten thus usp promis drug target howev systemat identif usp substrat yet perform studi carri proteom profil label free quantif control singledoubl ko cell usp closest homolog usp proteom profil first time reveal proteom chang caus usp andor usp deplet combin protein profil transcriptom analysi tandem affin purif usp associ protein compil list high confid usp substrat includ known novel usp substrat experiment valid mga phip new substrat usp show mga delet reduc cell prolifer similar observ cell usp delet conclus proteom wide analysi uncov potenti usp substrat provid resourc function studi
|
D040901;D043222
|
T116;T126;T091
|
36,302,554
|
singl molecul identif target rnas differ rna bind protein simultan cell rna bind protein rbps regul near everi aspect mrna process import regul gene express cell howev current method transcriptom wide identif rbp target limit sinc examin singl rbp time provid inform individu rna molecul bound given rbp overcom limit develop tribe stamp approach singl molecul detect target rnas two rna bind protein simultan cell appli tribe stamp cytoplasm reader protein ythdf ythdf ythdf discov individu mrna molecul bound one ythdf protein throughout lifetim provid new insight function ythdf protein cell tribe stamp high versatil approach enabl singl molecul analysi target rbp pair simultan cell
|
D016601;D012313
|
T123;T116;T114
|
36,302,553
|
integr saga tfiid pic assembl pathway select pois induc promot genom wide littl understood protein organ induc promot induct extent induc constitut architectur depend cofactor report sequenc specif transcript factor tether cofactor eg saga spt ada gcn acetyltransferas mediat tup nua swisnf rpd l general bound promot prior induct pois rather recruit upon induct wherea induct recruit preiniti complex pic dna deplet andor delet experi show saga function constitut promot although saga independ gcn acetyl nucleosom induc promot pois saga catalyz nucleosom acetyl pic assembl induc saga catalyz acetyl deubiquityl pic assembl surpris saga mediat induct creat pic allow tfiid transcript factor ii stabli associ rather creat complet tfiid independ pic general thought find suggest induc system present integr constitut system
|
D035362;D029701
|
T123;T116
|
36,302,537
|
colchicin anti inflammatori therapi non intens care unit hospit covid patient result pilot open label random control clinic trial system inflamm hallmark sever coronavirus diseas covid anti inflammatori therapi consid crucial modul hyperinflammatori respons cytokin storm hospit covid patient current specif conclus proven cost effici worldwid avail anti inflammatori therapi avail treat covid patient cytokin storm present studi aim investig treatment benefit oral colchicin hospit covid patient suspect cytokin storm colchicin approv drug possess multipl anti inflammatori mechan pilot open label random control clinic trial compar standard care soc plus oral colchicin colchicin arm vs soc alon control arm non icu hospit covid patient suspect cytokin storm colchicin treatment initi within first hour admiss deliv mg load dose follow mg bid next day mg qd second week total patient random alloc colchicin n control group n colchicin control group patient experienc similar clinic outcom day hospit treatment outcom day colchicin vs control arm recov discharg aliv vs remain admit day vs icu transfer vs mortal vs speed improv covid acut symptom includ short breath fever cough need supplementari oxygen oxygen satur level almost ident two group length hospit averag day shorter colchicin group evid differ two group follow serum level inflammatori biomark includ c reactiv protein crp dimer lactat dehydrogenas ldh ferritin interleukin il high sensit troponin hs tnt n termin pro b type natriuret peptid nt pro bnp accord result studi oral colchicin appear show clinic benefit non icu hospit covid patient suspect cytokin storm possibl anti inflammatori pathway colchicin crucial involv pathogenesi covid
|
D000086382
|
T047;T067
|
36,302,536
|
adenosin diphosph ribosyl factor like regul glycolysi lipogenesi relat gene colon cancer studi design investig potenti key gene adp ribosyl factor like arl regul glycolysi lipogenesi colon cancer hematoxylin eosin stain immunohistochemistri use observ express arl normal colon tissu colon cancer tissu immunofluoresc stain use observ express posit arl normal human colorect mucosa cell fhc colon cancer cell hct sw confoc microscop arl plasmid small interf rna sirna construct transfect express level glycolysi lipogenesi regulatori enzym messeng rna mrna transcript arl express silenc colon cancer cell detect western blot real time quantit pcr qrt pcr high express arl colon cancer tissu low express normal colon tissu express cytosol express posit arl fhc hct sw cell consist main distribut cytosol pcmv tag arl plasmid transfect hct protein express fasn akt p akt p gsk srebp p p ampk p higher control group mrna transcript level fasn gsk ampka srebp gene higher control group express arl arl sirna transfect hct protein express level pkm pfk fasn akt p akt p gsk ampk decreas compar control group p mrna transcript level fasn gsk ampk gene lower control group low express arl p ad jib arl hct show statist differ compar control group h h h p ad jib protein express level akt p gsk fasn ampk srebp hct cell decreas signific h also found express level akt p gsk fasn ampk srebp gene dose ad group signific lower control group summari arl may promot occurr colon cancer increas express protein kinas bamp activ protein kinas aktampk downstream regulatori enzym glycogenesi lipogenesi jib target arl affect express well express glucos lipid metabol relat protein akt ampk signal pathway
|
D003110;D051057;D020727
|
T191;T126;T116
|
36,302,535
|
independ associ fto rs polymorph overweight obes polish adult result repres popul base wobasz studi genet factor play import role origin obes investig associ fto rs genotyp overweight obes along addit anthropometr variabl repres sampl adult polish popul genotyp random sampl adult individu examin cross section popul survey wobasz men women least one allel aa genotyp found approxim one fifth men women frequenc aa genotyp increas higher bmi sex associ higher anthropometr obes indic men women fto rs aa genotyp signific relat abnorm bmi overweight obes men regardless age tobacco smoke physic activ diet diabet women relat abnorm bmi overweight adjust addit menopaus frequenc allel polish popul european countri one fifth men women fto rs aa variant signific relationship found fto genotyp anthropometr obes indic aa genotyp signific associ abnorm bmi overweight sex relat obes phenotyp observ men
|
D000071516;D009765;D050177
|
T033;T047;T126;T116
|
36,302,534
|
leptin vascular endotheli growth factor cross talk obes women gestat diabet diabet pregnanc cohort studi vascular endotheli growth factor vegf synthesi intensifi leptin hypoxia induc factor alpha hif nuclear factor kappa light chain enhanc activ b cell nfb depend manner studi aim investig associ leptin vegf serum level obes women hyperglycaemia third trimest pregnanc sixti obes pregnant women hyperglycaemia divid group accord bodi mass index bmi group bmi kgm group bmi kgm group bmi kgm enrol visit waist circumfer bodi mass height measur visit v gestat week gw visit v gw anthropometr blood pressur heart rate measur blood sampl collect perform blood level leptin vegf vegf receptor hif nfb interleukin alpha protein delta homolog nitric oxid glycat haemoglobin determin analys predictor biochem parametr involv leptin vegf cross talk multivari logist regress implement posit correl serum level leptin vegf found serum level hif v predictor highest quartil serum level vegf v v leptin serum level v predictor highest quartil hif serum concentr v group hif level higher v compar v conclud obes women hyperglycaemia third trimest pregnanc signific posit influenc serum leptin vegf synthesi serum level hif seem play import role leptin vegf cross talk nfb
|
D016640;D006943;D020738;D009765;D042461
|
T123;T116;T033;T125;T047
|
36,302,533
|
effect edaravon combin dl n butylphthalid level tumor necrosi factor alpha interleukin neuron specif enolas effect patient acut cerebr infarct studi observ effect edaravon combin dl n butylphthalid nbp serum level tumor necrosi factor alpha tnf interleukin il neuron specif enolas nse therapeut effect patient acut cerebr infarct aci purpos studi explor whether edaravon combin nbp could improv neurolog function patient aci total patient aci enrol studi patient random assign control group treat edaravon patient assign intervent group treat combin edaravon nbp cours treatment last day basic drug treatment group effect rate activ daili live score adl signific higher intervent control group differ statist signific p treatment administ nation institut health stroke scale score two group lower treatment score lower intervent compar control group differ statist signific p treatment administ serum level tnf nse signific lower intervent control group serum il level signific higher intervent control group differ statist signific p edaravon combin nbp improv neurolog function patient aci improv qualiti life signific decreas serum level tnf nse increas serum il level better effect combin therapi method adopt clinic treat patient aci
|
D002545;D020521
|
T047;T046
|
36,302,532
|
iron chelat effect lipid peroxid inflamm ventricular perform rat model isoproterenol induc acut myocardi stress acut cardiac patholog repres one lead caus death iron metabol recogn implic reactiv oxygen speci product lipid peroxid inflamm aim present studi assess iron chelat effect isoproterenol iso induc acut cardiac stress divid male wistar rat prevent secondari treatment group activ arm consist deferipron dfp lipid permeabl chelat mortal iso prevent secondari group analyz serum myocardi tissu paramet inflamm iron dynam lipid peroxid accompani ultramicroscopi histolog ultrasound deriv paramet left ventricular function result reveal iso mediat lipid peroxid inflamm allevi administr dfp neglig effect system ferroregul dynam global ventricular function assess ultrasound dfp administr cardiovascular stress associ decreas lipid peroxid inflamm without improv gross left ventricular paramet
|
D007531;D009206
|
T121;T131;T024;T109
|
36,302,531
|
effect salvianol cardiomyocyt remodel improv myocardi infarct calcineurinnuclear factor c activ cellb myosin heavi chain pathway regul enorm evid clinic experiment studi demonstr salvianol sal could treat cardiovascular diseas myocardi infarct mi under mechan still need explor studi aim investig effect sal cardiomyocyt remodel mi rat explor whether possibl mechan relat decreas myosin heavi chain mhc express cardiomyocyt via calcineurin nuclear factor c activ cell nfatc pathway mi model angiotensin ii induc primari myocardi cell obtain rat use studi treatment sal cardiac function assess color doppler echocardiographi mi area myocardi cell area heart mass index hmi analyz via masson hematoxylin eosin stain stain respect addit activ nfatc mhc mrna protein express myocardi tissu myocardi cell test via correspond method main includ real time fluoresc base quantit polymeras chain reaction rt qpcr western blot wb immunohistochemistri fluoresc stain analysi result obtain high dose sal vivo could perform benefici effect cardiomyocyt remodel mi rat main manifest improv fraction shorten eject fraction rate reduc mi area myocardi cross section area hmi p inhibit activ myocardi tissu regul b mhc mrna protein express decreas nuclear transloc nfatc p vitro experi moll sal could inhibit increas myocardi cell area activ regul mrna protein subunit mhc inhibit nuclear transloc nfatc p conclus use sal improv cardiomyocyt remodel regul express mhc cardiomyocyt mechan might relat reduct nuclear transloc nfatc well regul cana subunit express andor inhibit activ result provid laboratori basi clinic applic sal
|
D019703;D009203;D032383;D018995;D010936
|
T123;T121;T116;T025;T126;T047
|
36,302,530
|
review benefit advers effect common use local anesthet adjuv peripher nerv block recent peripher nerv block extens appli mani patient undergo surgic nonsurg analgesia howev effect limit durat action local anesthet therefor applic ad local anesthet adjuv evolv prolong durat analgesia decreas concentr local anesthet peripher nerv block mani local anesthet adjuv avail morphin fentanyl sufentanil hydromorphon buprenorphin dexmedetomidin dexamethason midazolam magnesium sulfat safe possess littl advers effect none acknowledg food drug administr therefor review aim delin benefit advers effect clinic anesthesia
|
D009407;D000698
|
T061
|
36,302,529
|
endotheli lipas regul biolog function endotheli lipas synthet almost exclus endotheli cell fix lumin surfac endothelium mean heparan sulphat proteoglycan enzym express endothelium near tissu degre express higher rich vascular tissu less vascular one endotheli lipas express tissu upregul shear cyclic stress angiotensin ii hypertens plasma enzym level elev pro inflammatori cytokin metabol syndrom obes prolong exercis reduc plasma enzym level rat activ enzym inhibit sphingomyelin angiopoietin like protein insulin endotheli lipas reduc plasma high densiti lipoprotein concentr chang properti enzym consid main regul plasma high densiti lipoprotein concentr plasma endotheli lipas concentr elev coronari atherosclerosi invers correl plasma high densiti lipoprotein level enzym consid exert most pro atherogen effect action triglycerid lipas import hypertriglyceridemia
|
D050197;D008071
|
T047;T046;T126;T116
|
36,302,508
|
one pot biosynthesi l aspart maleic anhydrid via thermost dual enzym system high temperatur l aspart import chemic food pharmaceut industri herein dual enzym system construct synthes l aspart maleic anhydrid c reduc byproduct product maleat transform maleic anhydrid solut convert l aspart via fumar catalyz maleat isomeras maia thermost aspartas aspb respect maia rate limit enzym enzym activ various maia compar effici thermost maleat isomeras aa maia alicyclobacillus acidoterrestri chosen k cat k valu aa maia mm min aa maia aspb coexpress e coli produc l aspart improv l aspart product rate ribosom bind site rbs sequenc locat upstream aa maia optim tat signal peptid fuse aa maia convers rate within min intermedi detect possibl reason high temperatur inhibit activ bacteri endogen enzym function enzym remain activ cell ferment produc gl l aspart substrat studi reveal effect method produc l aspart without use gene knockout provid strategi l aspart product industri field
|
D001224;D001220
|
T123;T121;T116;T109;T126
|
36,302,458
|
daili step volum intens moder associ sedentari time cardiometabol diseas risk communiti dwell older adult cross section studi investig moder effect step count peak cadenc relationship sedentari time cardiometabol diseas risk communiti dwell older adult
|
D057185;D002318
|
T033;T047;T079
|
36,302,457
|
comparison manual autom measur walk speed distanc pace matter walk speed ws repres global marker individu health provid simpl object measur motor perform use clinic research set ws often measur relat short distanc usual uw fast fws pace use manual eg stopwatch autom method eg photoelectr cell time need walk distanc short hypothes measur error relat manual compar autom ws measur pronounc shorter distanc fws investig reliabl agreement ws subsampl constanc cohort two pace two distanc
|
D000072797;D016138
|
T056;T032;T169
|
36,302,456
|
associ leukocyt telomer length perceiv physic fatig leukocyt telomer length ltl potenti genom marker biolog age relat fatig prognost indic phenotyp age eg function declin unknown hypothes shorter ltl would predict greater perceiv physic fatig associ would attenu adjust chronolog age
|
D016615;D007962
|
T026;T025
|
36,302,383
|
effect incent improv diabet relat health indic chronic diseas lifestyl modif program systemat review meta analysi examin effect provid incent particip lifestyl modif program improv diabet relat health indic bodi weight bodi mass index bmi blood pressur cholesterol hemoglobin c hba c also examin potenti effect differ incent domain ie type monetari valu attain certainti schedul indic
|
D009042;D003920
|
T078;T047;T041;T080
|
36,302,382
|
dispar influenza vaccin coverag associ factor among adult cardiovascular diseas unit state influenza vaccin reduc incid cardiovascular diseas cvd us howev differ state level trend cvd sociodemograph health care characterist adult cvd yet studi
|
D007251;D002318;D007252
|
T129;T047;T121;T109
|
36,302,381
|
qualit studi percept strength opportun cardiometabol risk manag pregnanc postpartum georgia safeti net hospit despit strong link cardiometabol pregnanc complic futur heart diseas document gap engag experi condit recommend postpartum follow prevent care goal studi understand peopl medicaid insur popul perceiv manag risk pregnanc relat ongo cardiometabol disord
|
D011248;D046110;D006331
|
T047;T046
|
36,302,377
|
long term impact covid present specialist child adolesc eat disord program aim explor impact covid number clinic profil eat disord ed present specialist ed program pre covid method retrospect chart review referr pre covid januari februari covid march august compar result youth assess signific higher rate referr month covid compar pre covid vs p youth refer covid show higher rate ideal bodi weight ibw loss vs p lt shorter durat ill pre referr month vs month p fewer youth covid vs p prescrib psychotrop medic mani youth self declar covid contributori factor develop ed conclus studi support grow consensus covid specif impact ed servic higher rate referr youth present faster pace weight loss earlier referr specialist servic whether repres true increas ed overal increas camh referr faster transfer ed servic requir explor
|
D000086382;D001068
|
T047;T067;T048
|
36,302,375
|
potent monoclon antibodi neutral omicron sublineag sar cov variant emerg global spread sar cov omicron variant carri unpreced number mutat rais serious concern due reduc efficaci current vaccin resist therapeut antibodi report generat character two potent human monoclon antibodi na ne receptor bind domain sar cov spike protein na interact high conserv region breadth neutral picomolar potenc beta variant omicron ba ba sublineag nanomolar potenc ba ba combin na ne retain potent neutral activ major sar cov variant concern cryo em analysi provid structur basi broad complementari neutral activ two antibodi confirm vivo protect therapeut efficaci na ne hamster model result show broad potent human antibodi overcom continu immun escap evolv sar cov variant
|
D000086382;D000074322
|
T129;T121;T116;T067;T047
|
36,302,370
|
character spermatozoon ultrastructur tetragonocephalum sp cestoda lecanicephalidea tetragonocephalida whipray urogymnus asperrimus dasyatida urogymnina lecanicephalidea repres one current recogn elasmobranch host tapeworm lineag quit specios near valid recogn speci date yet spermatozoon featur fulli character singl speci spermatozoon charact second speci previous includ data matrix use infer phylogenet relationship among cestod order data limit imag provid specimen tetragonocephalum sp collect whipray urogymnus asperrimus solomon sea solomon island matur spermatozoa tetragonocephalum sp distinct differ lecanicephalidean speci spermatozoon ultrastructur thorough investig tetragonocephalum sp spermatozoa repres type iv sensu levron morpholog possess singl axonem crest bodi cortic microtubul run parallel axonem nucleus helic axonem although spermatozoa lecanicephalidean examin date type iv spermatozoon morpholog differ number crest bodi cortic microtubul relat size spermatozoon specif relat nuclear region presenc absenc anterior spiral structur signific spermatozoon charact variat present across repres lecanicephalidean famili indic addit studi repres famili order need better understand extent charact variat present lecanicephalidea overal spermatozoon ultrastructur understudi elasmobranch host tapeworm lineag compar vertebr host tapeworm order speci famili level
|
D002589;D002590;D012860
|
T047;T204;T013
|
36,302,369
|
revis coronoepimeritus descript coronoepimeritus otoensi n sp infect admir grasshopp syrbula admirabili orthoptera acridida herein reaffirm valid coronoepimeritus junior synonym quadruspinospora provid new combin exist speci quadruspinospora recogn monospinospora n gen receiv coronoepimeritus monospinus describ coronoepimeritus otoensi n sp alimentari canal admir grasshopp syrbula admirabili orthoptera acridida nemaha counti n w near peru nebraska specimen differ known speci differ total gamont length tl oocyst length ol oocyst spine length osl coronoepimeritus atractomorphii n comb like new speci basi ol osl respect speci new speci possess gamont whose tl less report c atractomorphii averag tl vs respect nucleotid sequenc phylogenet analys confirm placement new speci coronoepimeritus k test ratio averag distanc separ speci level clade genet divers clade consist speci distinct known sequenc sampl group coronoepimeritus mexicana n comb
|
D006110
|
T204
|
36,302,366
|
parent percept regard impact hous child health introduct childhood poverti life long advers impact aim assess percept parent cohort children attend paediatr emerg depart regard impact hous child famili method cross section studi perform paediatr emerg depart dublin result parent complet questionnair n report homeless homeless children less like regist general practition vs p fulli vaccin vs p homeless parent like feel unsaf home vs p lt report hous negat impact child educ vs p lt physic health vs p mental health vs p lt ten percent non homeless parent concern lose home lack landlord permiss instal child safeti measur home report parent conclus homeless parent like report live situat negat impact child play develop educ safeti health
|
D006798;D006703
|
T033;T098;T095;T073
|
36,302,351
|
assess patient satisfact kidney stone inform advic admiss acut renal colic aim studi focus assess patient report outcom measur prom follow educ intervent urolog servic provid modern era social media search engin use educ tool patient healthcar provid alik aim studi assess patient satisfact kidney stone inform view novel kidney stone educ video method prospect qualiti improv studi conduct amongst patient admit urolog servic kidney stone undergo emerg ureteroscopi use patient satisfact questionnair result patient report increas satisfact overal inform provid kidney stone prevent view kidney stone educ video vs p also report increas satisfact inform provid diet lifestyl modif vs p vs p inform demonstr stent remov vs p inform stent pain vs p avail educ inform resourc view video vs p patient total includ statist analysi conclus patient satisfact tradit patient educ regard kidney stone strengthen use concis inform readili access patient educ video point care
|
D056844;D007669
|
T184;T047
|
36,302,350
|
air pollut level outsid capit matern hospit introduct world health organis identifi air pollut singl biggest environment threat human health grow evid literatur air pollut associ negat outcom pregnanc purpos studi measur pollut level immedi surround three dublin matern hospit measur fine particul matter lt micrometr pm method data pertain level pm three dublin matern hospit obtain pollutrack record time period result compar air qualiti guidelin result averag pm level gm around nation matern hospit gm around coomb hospit gm around rotunda hospit level higher day weekday decemb matter pm level measur result higher recommend world health organis air qualiti guidelin discuss air pollut level across ireland capit citi higher recommend concern public particular pregnant popul go forward research requir relationship level air pollut advers pregnanc outcom dublin
|
D000397;D000393
|
T131;T069;T080
|
36,302,332
|
hdacjak dual target inhibitor cancer relat target success nonclear link pharmacophor mode recent year develop dual target drug becom research hotspot cancer treatment reason design drug critic nonclear link pharmacophor mode one common use strategi design dual target drug connect pharmacophor two synergist target inhibitor one molecul linker great improv util drug epigenet modif potenti treatment multipl diseas alway subject great concern histon deacetylas hdac play import role janus kinas jak famili intracellular non receptor tyrosin kinas transduc cytokin mediat signal jak signal transduc activ transcript stat pathway studi show combin hdac jak inhibitor exhibit synergist effect breast cancer treatment addit pharmacophor model aforement two inhibitor indic similar essenti featur investig recent year progress field demonstr nonclear link pharmacophor mode use differ length carbon chain linker connect pharmacophor two inhibitor main strategi design hdacjak dual target inhibitor verifi effect biolog activ test review take recent year hdacjak dual target inhibitor develop detail exampl summar general idea behind scene wish provid reader theoret basi develop effici dual target multi target drug futur
|
D000075242;D009369
|
T121;T191
|
36,302,330
|
liposom base artifici cell gene express reconstitut cellular function phenotyp bottom approach creat artifici cell mimic natur cell signific implic basic research translat applic among various artifici cell model liposom one sophist system encapsul protein associ biomolecul function reconstitut foundat featur biolog cell abil divid communic undergo shape deform yet construct liposom artifici cell genet level central generat self sustain system remain high challeng inde mani studi success establish express gene code protein insid liposom recent endeavor build direct integr gene express protein reconstitut molecular function phenotyp liposom also signific increas thus review present develop liposom base artifici cell demonstr process gene express protein reconstitut perform desir molecular cell like function molecular cellular phenotyp discuss includ self product membran phospholipid divis shape deform self dnarna replic fusion intercellular communic togeth review give comprehens overview gene express liposom stimul research technolog achiev artifici cell superior properti futur
|
D058045
|
T073;T075
|
36,302,329
|
effect microneedl shape skin penetr transderm drug administr microneedl mn patch high effici versatil tool transderm drug administr particular pain free self medic rapid local applic diffract ultraviolet uv light lithographi offer advanc method fabric poli ethylen glycol base mns differ shape chang uv light exposur time photomask design exposur time interv limit obtain conic structur aspect ratio otherwis mns exhibit reduc fractur load poor indent abil suitabl practic applic therefor work focus systemat analysi mn base shape effect structur characterist skin penetr drug deliveri analyz four differ base shape circl triangl squar star found number vertic polygon base heavili affect properti star like mns reveal effici skin penetr abil equal length due edg action skin perfor furthermor quantif drug deliv mns ex vivo porcin skin show amount small molecul releas h star like mns coat local anesthet lidocain anti inflammatori diclofenac epolamin drug higher circular mns respect
|
D009339;D012867
|
T022;T074
|
36,302,306
|
choroid plexus deriv extracellular vesicl exhibit brain target characterist brain protect invad organ unwant substanc tight regul barrier howev central nervous system cns barrier imped deliveri drug brain via blood circul therefor consid major hurdl treatment neurolog disord consequ high need effici deliveri system abl cross strict barrier research focus blood brain barrier bbb design drug deliveri platform abl cross blood cerebrospin fluid csf barrier form singl layer choroid plexus epitheli cell remain larg unexplor domain discoveri extracellular vesicl ev make natur mechan inform transfer cell across cell layer stimul interest potenti use drug deliveri platform report choroid plexus epitheli cell deriv ev exhibit capac home brain peripher administr moreov vesicl abl function deliv cargo brain find underlin therapeut potenti choroid plexus deriv ev brain drug deliveri vehicl via target blood csf interfac
|
D002831;D000067128
|
T026;T023
|
36,302,305
|
dual tumor subcellular target photodynam therapi use glucos function mos nanoflak multidrug resist tumor ablat photodynam therapi pdt emerg effici strategi combat multidrug resist mdr cancer howev short half life limit diffus reactiv oxygen speci ros undermin therapeut outcom therapi address issu tumor target nanoplatform develop precis deliv mitochondria endoplasm reticulum er target pdt agent desir site dual organell target pdt nanoplatform construct function molybdenum disulfid mos nanoflak glucos modifi hyperbranch polyglycerol hpg load organell target pdt agent result nanoplatform cy tg gpm demonstr mediat great enhanc intern within mdr cell precis subcellular local pdt agent facilit situ near infrar nir trigger ros generat augment pdt revers mdr caus impress tumor shrinkag hela multidrug resist tumor mous model reveal mechanist studi synergist mitochondria er target pdt ros induc er stress activ cytosin cytosin adenosin adenosin thymidineenhanc bind protein homolog protein chop pro apoptot signal pathway also cooper ros induc mitochondri dysfunct trigger cytochrom c releas mitochondria induc subsequ cell death furthermor mitochondri dysfunct reduc atp product therebi contribut revers mdr nanoplatform nir respons properti abil target tumor subcellular organell offer promis strategi effect mdr cancer therapi
|
D010778;D053758
|
T061;T073
|
36,302,304
|
one step synthesi b enrich bpo nanoparticl effect boron neutron captur therapeut treatment recurr head neck tumor recurr head neck h n cancer one malign cancer world various treatment modal radiat therapi chemotherapi surgeri adopt treat h n cancer recurr h n tumor alway occur lead poor prognosi low year surviv rate recent boron neutron captur therapi bnct emerg altern modal cure recurr tumor present boron phenylalanin fructos bpa f sodium borocapt bsh two best bnct molecular drug howev poor therapeut efficaci lack tumor target abil studi b rich b boron phosphat nanoparticl bpo nps nm size prepar singl step use uniqu microwav arc method b enrich bpo nps surfac modifi anti egfr antibodi endow target abil toward h n cancer cell vivo xenograft mice model larg amount g bg cancer cell b atom could effect accumul h n tumor site use bpo nps bnct reagent vitro neutron irradi experi cell death observ anti egfr bpo nps treat h n cancer cell fold higher treat effect molecular drug bpa f demonstr upon neutron irradi anti egfr bpo nps could exert much higher extent destruct h n tumor well effect suppress probabl h n tumor recurr compar effect molecular drug bpa f median surviv bnct treat mice anti egfr bpo nps extend beyond day far better mice treat bpa f day blank nr mice blank mice day
|
D016754;D006258;D053758
|
T061;T191;T073
|
36,302,298
|
vancomycin resist enterococci patient attend colonoscopi estim communiti preval aim ireland highest vancomycin resist enterococcus faecium vre bloodstream infect preval europ two pattern vre carriag recognis european widespread communiti preval north american carriag predomin nosocomi unclear pattern domin ireland uncertainti limit infect control measur studi sought explor issu via cross section point preval studi method asymptomat communiti volunt repres patient undergo elect outpati colonoscopi test opportunist screen vre demograph risk factor data collect via patient survey rectal swab collect colonoscopi vre identifi use vitek ms system result patient cultur singl patient test posit repres preval rate ci lt patient demonstr tradit risk factor suggest nosocomi rather communiti acquisit n patient knowledg vre n low level concern regard hospit acquir infect conclus low incid vre irish communiti set contrast european countri suggest asymptomat communiti colon respons high rate vre seen ireland wider screen atyp infect control measur would support data
|
D065507;D003428;D016908
|
T047;T007
|
36,302,280
|
synergist remov u vi aqueous solut tac materi adsorpt behavior mechan adsorpt recoveri uranium wastewat posit signific develop nuclear industri environment remedi ternari polym pzs co ta prepar hexachlorocyclotriphosphazen hccp sulfonyldiphenol bps tannic acid ta ultrason tac obtain carbon high temperatur pzs co ta structur perform tac analyz use sem ed ft ir xrd raman bet tg adsorpt capac tac uranium differ static adsorpt condit investig adsorpt process consist pseudo second order model maximum adsorpt capac calcul non linear langmuir model mgg ph thermodynam valu suggest adsorpt process spontan endotherm moreov five cycl adsorpt desorpt test tac remain effect adsorb uranium impli introduc ta precursor pzs co ta could enhanc adsorpt capac uranium
|
D014501
|
T196
|
36,302,271
|
nutrient limit phytoplankton three tributari chesapeak bay detect respons follow nutrient reduct mani coastal ecosystem suffer eutroph algal bloom dead zone due excess anthropogen input nitrogen n phosphorus p led region restor effort focus manag watersh load n p chesapeak bay largest estuari unit state dual nutrient reduct n p pursu sinc howev remain unclear whether nutrient limit indic restrict algal growth suppli n p chang tributari chesapeak bay follow decad reduct effort toward end analyz histor data nutrient addit bioassay experi data chesapeak bay long term water qualiti monitor program six station three tidal tributari ie patux potomac choptank river classif regress tree cart model develop use concurr collect water qualiti paramet bioassay monitor locat satisfactorili predict bioassay base measur nutrient limit classif accuraci predict cart model use water qualiti monitor data show enhanc nutrient limit period four six station includ downstream station three tributari result indic detect long term water qualiti improv tidal tributari overal research provid new analyt tool detect sign ecosystem recoveri follow nutrient reduct broad approach adapt waterbodi long term bioassay water qualiti data set detect ecosystem recoveri
|
D010839;D017753
|
T082;T070;T002
|
36,302,270
|
maintain long term accuraci water distribut model data assimil method compar studi upgrad water suppli servic call accur adapt numer model give insight actual water distribut system wdss underlin import care calibr model paramet due unavoid uncertainti calibr process measur error error model paramet assum known local optimum calibr algorithm calibr paramet could still contain non neglig latent error calibr model may abl maintain long term accuraci oper condit chang solv problem grow interest adopt data assimil da method util comprehens inform long term measur reduc impact uncertainti maintain accuraci stabil calibr model studi two tradit calibr method four da method test compar two wdss differ structur aim form general understand behavior applic differ method calibr result show da method perform better tradit method robust differ type uncertainti provid effect way maintain long term accuraci wds model enabl better manag wdss ensembl base da method particl filter pf inferenti measur kalman filter imkf perform well real life system avoid linear approxim better estim impact uncertainti assimil accur correct inform paramet gradient base da method extend kalman filter ekf variat bayesian adapt kalman filter vbakf lower comput demand found less robust deal larg system uncertainti nonlinear
|
D014867;D000465
|
T121;T197;T170
|
36,302,268
|
bacteriolog profil earli onset sepsi eo late onset sepsi los neonat aim audit perform see bacteriolog profil earli onset sepsi eo late onset sepsi los compar microorgan identifi antibiot sensit result hospit guidelin empir treatment earli late onset sepsi method retrospect collect neonat microbiolog data laboratori includ date blood cultur bc sampl collect patient day life sampl collect determin whether eo los time posit bc antibiot suscept result result eo infect caus gram posit organ isol gbs common pathogen identifi los number infect caus gram negat organ isol higher caus gram posit organ isol e coli identifi lead pathogen caus bsi organ sensit antibiot use accord protocol conclus escherichia coli common organ sensit first line antibiot use group b streptococcus still main pathogen eo rate antibiot resist low audit show import analys bacteriolog antibiot suscept pattern ensur optim treatment administ infant
|
D018805;D004927
|
T047;T046
|
36,302,263
|
miniatur carbon fiber paper electrod situ high resolut nmr analys combin spectroscop techniqu electrochemistri promis strategi allow detail investig speci consum produc reaction real time howev situ coupl techniqu junction nmr electrochemistri present challeng notabl distort nmr signal due placement electrod close within detect region work miniatur electrod made carbon fiber paper develop later modifi platinum platinum decor cathod deposit chosen platinum promin element electrocatalysi abl catalyz larg varieti reaction evalu effici electrochem system oxid ascorb acid use model reaction observ electrod caus substanti signal distort place within detect region full width half maximum equal hz wherea distort observ electrod place mm detect region full width half maximum equal hz system also possibl monitor magnetoelectrolysi effect caus interact magnet field flow ion lead doubl ascorb acid oxid rate compar reaction perform without magnet field addit low cost simplic prepar develop electrod system allow electrod surfac easili modifi suitabl catalyst
|
D010984;D001205
|
T121;T196;T127;T109
|
36,302,246
|
spindl cell lipoma epiglotti potenti airway emerg nil
|
D004825;D008067
|
T023;T191
|
36,302,245
|
sever cutan reaction messeng rna mrna bntb pfizer biontech vaccin pathway covid pandem reliant uptak vaccin new zealand access messeng rna mrna bntb pfizer biontech vaccin case report discuss patient present acut general medic servic sever cutan advers reaction scar vaccin featur steven johnson syndrom acut generalis pustulosi earli recognit manag scar requir prevent morbid mortal
|
D000086382;D014612
|
T129;T121;T116;T067;T047
|
36,302,244
|
radiolog te whatu ora health new zealand care radiolog key enabl clinic activ shown high cost effect demand activ increas time demand comput tomographi ct magnet resourc imag mri ultrasound us grow faster popul growth complex also increas time resourc public sector kept demand exacerb covid pandem relianc oversea train workforc result critic shortag wait time ct mri us across aotearoa new zealand remain well target improv year robust link clinic activ radiolog resourc need address deficit therebi maintain clinic safeti
|
D000086382;D011871
|
T047;T091;T067
|
36,302,243
|
microvascular reconstruct outcom new zealand oral maxillofaci surgeri unit oral maxillofaci surgeri om depart waikato district health board wdhb current om unit within new zealand reconstruct oral caviti defect microvascular free flap primari object studi retrospect analys demograph outcom complic free flap surgeri patient wdhban om reconstruct databas develop data collect retrospect free flap perform patient femal male mean median age respect tongu common site resect squamous cell carcinoma frequent diagnosi radial forearm free flap use often follow fibula anterolater thigh flap clavien dindo classif use classifi complic patient major complic patient minor complic flap success rate meet intern accept standard care
|
D019651;D013515
|
T061;T091
|
36,302,242
|
effect covid orthopaed aotearoa new zealand survey orthopaed surgeon train registrar studi aim assess impact covid orthopaed practic new zealand focus train mental health
|
D009985;D000072161;D000086382;D019637
|
T061;T091;T067;T097;T047
|
36,302,241
|
audit southern dhb b school hear screen referr process unmet need b school check aim earli detect appropri manag hear loss prior school entri light increas awar inequit health outcom across varieti measur aotearoa new zealand particular mori pasifika perform audit b school screen hear relat referr
|
D012017;D034381
|
T033;T170;T097;T058;T047
|
36,302,240
|
improv earli detect colorect cancer aotearoa new zealand direct access criteria perform colorect cancer crc common malign new zealand increas pressur investig resourc diagnosi nation direct access referr guidelin ministri health moh guid refer investig perform detect crc signific diseas report previous paper describ yield direct access criterion referr direct access pathway canterburi district health board cdhb
|
D015179;D023881;D015212
|
T060;T047;T191
|
36,302,239
|
doctor view impact absenc person rheumatolog servic major new zealand hospit describ view doctor one hospit servic impact lack person rheumatolog consult servic identifi servic improv inform view servic compar district health board dhb
|
D010820;D012219
|
T091;T097
|
36,302,238
|
risk factor readmiss patient acut diverticul retrospect studi auckland citi hospit approxim one five patient acut diverticul ad experi recurr studi aim investig factor ad admiss correl recurr test propos risk recurr score accord sallinen et al method retrospect studi follow patient five year admit oper comput tomographi ct verifi ad auckland citi hospit januari june demograph laboratori radiolog patient relat factor initi admiss analys relat readmiss recurr ad test risk score present sallinen et al result adjust analys previous diagnosi ad ci mori ethnic ci complic ad index admiss ci independ factor associ readmiss recurr high risk versus low risk group accord risk score show recurr rate respect
|
D004238;D004239
|
T047
|
36,302,237
|
suicid amongst doctor nil
|
D013405;D010820
|
T033;T097
|
36,302,226
|
vital sign influenza hospit vaccin coverag race ethnic unit state influenza season cdc estim influenza result million ill hospit death annual person racial ethnic minor group histor experienc higher rate sever influenza lower influenza vaccin coverag compar non hispan white white person report examin influenza hospit vaccin rate race ethnic year period influenza season
|
D007251;D007252
|
T129;T047;T121;T109
|
36,302,225
|
burden impact chronic cough sever diseas chronic cough common sever diseas copd interstiti lung diseas lung cancer heart failur negat effect qualiti life spite patient cough sometim feel cough neglect healthcar worker review aim briefli describ cough mechan highlight burden chronic cough individu clinic impact chronic cough
|
D017563;D029424
|
T047
|
36,302,212
|
bulk affin assay aptam select challeng theori workflow select oligonucleotid aptam involv consecut round affin isol target bind oligonucleotid random sequenc oligonucleotid librari everi next round produc aptam enrich librari progress higher fit tight bind target progress enrich accur assess bulk affin assay librari mix target one two quantit paramet fraction unbound librari r equilibrium dissoci constant k determin quantit paramet use help research make key decis either continu stop select despit import decis suitabl r k bulk affin assay never studi theoret research reli intuit choos differ approach use bulk affin assay expect hinder compar analys select current work two goal give bulk affin assay thorough theoret consider propos scientif justifi practic bulk affin assay approach postul formal criterion suitabl quantit paramet must satisfi principl superposit r satisfi principl k suggest r theoret prefer paramet propos solut two limit r depend target concentr narrow dynam rang final demonstr use algorithm comput simul experiment aptam select studi set cornerston theori bulk affin assay provid research scientif sound instruct approach conduct bulk affin assay
|
D052157
|
T114
|
36,302,211
|
checklist cognit aid underutil research tool promot patient safeti optim clinician perform checklist cognit aid serv multipl purpos peri oper set becom near ubiquit healthcar review lay evid use shortcom pitfal awar technolog innov may improv checklist cognit aid relev usabl
|
D057189;D061214
|
T058;T170
|
36,302,209
|
develop implement databas track patient safeti outcom recent advanc big data analyt tool larg patient databas expand tremend opportun track patient safeti outcomesw discuss strength limit larg databas implement practic focus current opportun use technolog advanc improv patient safeti
|
D057286;D000077558
|
T170;T073
|
36,302,208
|
region anaesthesia surgic procedur block avail block room expect rise day care procedur enhanc recoveri program use specif region anaesthesia use review provid insight use region block medic far known applic day care set
|
D000779;D000765
|
T061;T121;T109
|
36,302,207
|
schedul staff ambulatori anaesthesia studi summar six articl publish januari june cover anaesthesia staff schedul consid relev ambulatori surgeri staff schedul refer plan shift length person work specif date
|
D007396;D000086382;D000758
|
T061;T067;T097;T065;T047
|
36,302,202
|
map cluster analysi research psychiatr genom distribut pattern knowledg structur psychiatr genom survey base literatur deal psychiatri genomicsgenet coword analysi bibliograph coupl record retriev scopus pubm reveal subsurfac research aspect
|
D015706;D012559
|
T062;T048
|
36,302,199
|
neurotrauma review highlight latest research relev clinic care traumat brain injuri tbi patient last year underscor implic advanc understand diagnosi treatment prognosi tbi
|
D000070642;D054556
|
T047;T037
|
36,302,198
|
coronavirus diseas aftermath psycholog trauma icu healthcar worker aim describ extent psycholog trauma moral distress healthcar worker hcw work intens care unit icu coronavirus diseas covid pandem specif review report preval mental health symptom highlight vulner popul summar modifi risk factor associ mental health symptom icu hcw
|
D000086382;D002055;D000067073
|
T047;T067;T048
|
36,302,195
|
provid respiratori ventil care face shift evid current opinion critic care review clinic problem noninvas treatment hypoxemia critic ill patient coronavirus diseas pneumonia describ recent advanc evid support bedsid decis make
|
D000086382;D063087;D012131
|
T061;T047;T046;T067
|
36,302,194
|
fluid balanc pediatr critic ill patient without kidney dysfunct issu fluid balanc fluid overload current consid crucial aspect pediatr critic ill patient care
|
D014883;D058186
|
T047;T046;T037
|
36,302,191
|
constel rare gynecolog malign famili adenomat polyposi gastrointestin adenocarcinoma case report ovarian microcyst stromal tumor mst rare subtyp sex cord stromal tumor present case mst aris patient famili adenomat polyposi fap concurr colon adenocarcinoma patient workup ampullari adenoma associ fap found enlarg uterus thicken endometrium incident pelvic mass fundus uterus subsequ imag identifi heterogen bulki ovari patient underw surgic resect includ total abdomin hysterectomi bilater salpingo oophorectomi omentectomi bilater pelvic sentinel lymph node biopsi plan total proctocolectomi transduoden ampullectomi extens histolog immunohistochem investig complet final patholog report reveal uniqu compil intern feder gynecolog obstetr stage ii grade endometrioid endometri adenocarcinoma bilater ovarian mst sperat peduncul mass favor diagnosi uterin tumor resembl ovarian sex cord tumor utrosct distinct adenocarcinoma colon tn tn tubular adenoma ampulla patholog show endometroid adenocarcinoma catenin negat mst utrosct show nuclear posit catenin knowledg first report case utrosct concurr endometri adenocarcinoma present bilater ovarian mst adenomat polyposi coli gene posit fap colon adenocarcinoma
|
D000230;D003110;D018312;D011125;D014594;D010051;D000236
|
T047;T191
|
36,302,190
|
uterin sarcoma fgfr tacc gene fusion case report review literatur grow avail rna sequenc technolog patholog laboratori new gene fusion associ malign increas character articl describ second ever report case uterin sarcoma harbor fgfr tacc gene fusion patient yr old perimenopaus woman found cm mass span lower uterin segment endocervix histolog spindl cell neoplasm coagul necrosi moder cytolog atypia increas mitot activ immunohistochemistri neoplast cell coexpress cd lack smooth muscl marker express rna sequenc reveal presenc fgfr tacc gene fusion report provid evid suggest fgfr tacc may recurr fusion subset uterin sarcoma rna sequenc use panel includ fgfr tacc famili fusion consid uterin sarcoma fit convent diagnost criteria particular tumor fusion may amen target therapi
|
D012509;D012983;D014594
|
T191
|
36,302,189
|
postchemotherapi endometrioid gastrointestin histotyp shift recurr endometri carcinoma herein report case low grade endometri endometrioid carcinoma recur vagin stump show complet histotyp shift toward gastrointestin type carcinoma chemotherapi recurr tumor increas volum chemotherapi postchemotherapi histolog examin show pure mucin signet ring cell pattern posit cytokeratin cdx focal satb express negat cytokeratin estrogen progesteron receptor featur led consid diagnosi metastasi primari carcinoma gastrointestin tract accur exclus primari lesion gastrointestin site allow identifi tumor recurr endometri carcinoma case highlight chemotherapi may induc histotyp shift endometrioid carcinoma gastrointestin type carcinoma occurr might mechan resist might provid new insight sensit differ histotyp system therapi consid possibl shift endometrioid gastrointestin type carcinoma may use correct diagnosi appropri patient manag
|
D018269;D016889;D005770
|
T191
|
36,302,188
|
leiomyo adenomatoid tumor uterus find rare routin leiomyo adenomatoid tumour lmat rare benign neoplasm case lmat uterus document literatur uterin lmat usual detect incident histopatholog evalu routin myomectomi hysterectomi specimen leiomyomata thorough evalu morpholog featur concis immunohistochem panel allow accur classif benign neoplasm
|
D018254;D014594;D007889;D063186
|
T061;T191
|
36,302,183
|
angiograph clinic outcom patient versus without diabet mellitus revascular biomim sirolimus elut stent drug elut stent des signific improv angiograph clinic outcom compar bare metal stent patient diabet clinic effect biomim sirolimus elut stent ses patient diabet evalu therefor compar efficaci biomim des coronari arteri diseas cad patient versus without diabet
|
D054855;D023903;D003324;D003920
|
T047;T074
|
36,302,181
|
discoveri prolin base pcbp inhibitor use dna encod librari technolog combin high throughput screen ea bind protein p creb bind protein cbp two high homolog multidomain histon acetyltransferas two protein involv mani cellular process act coactiv larg number transcript factor dysregul pcbp found varieti cancer diseas inhibit shown decreas myc express herein report identif seri high potent prolin base small molecul pcbp histon acetyltransferas hat inhibitor use dna encod librari technolog combin high throughput screen strategi reduc chromlogd fluorin metabol soft spot explor improv pharmacokinet properti potent p inhibitor fluorin cyclobutyl prolin ring led reduc clearanc also improv cmyc cellular potenc
|
D050882;D057166
|
T059;T116
|
36,302,160
|
autom segment flow analysi nmr novel fluoropolym flow cell high throughput screen high throughput analysi field industri biotechnolog combinatori chemistri life scienc becom increas import nuclear magnet reson nmr spectroscopi power techniqu provid exhaust molecular inform complex sampl flow nmr particular cost time effici method larg screen studi develop novel mm inner diamet polychlorotrifluoroethylen pctfe flow cell segment flow analysi sfa nmr autom platform platform use fc fluorin oil fluoropolym compon achiev fulli fluorin flow path sampl repeat transfer deepwel plate flow cell displac fix volum oil transfer time h spectra acquir fulli autom mhz nmr spectromet spectral perform novel pctfe cell equal commerci glass cell peak area repeat excel relat standard deviat standard sampl carryov without intermedi wash sampl temperatur condit use thermost transfer line order reduc equilibr time probe increas throughput final analysi urin sampl demonstr applic platform screen complex matric
|
D057166;D008279
|
T060;T170;T059
|
36,302,159
|
immedi versus delay postpartum insert contracept implant iud contracept long act revers contracept larc includ intrauterin devic iud contracept implant high effect revers method contracept provid larc method postpartum period import support contracept choic prevent unintend pregnanc short interpregn interv delay offer contracept postpartum peopl first comprehens postpartum visit tradit around six week postpartum may put postpartum peopl risk unintend pregnanc either due loss follow initi sexual intercours prior receiv contracept therefor immedi provis high effect contracept prior discharg hospit potenti improv contracept use prevent unintend pregnanc short interpregn interv
|
D011372;D007434
|
T125;T121;T039;T074
|
36,302,144
|
introduc multipl gene mutat pleurotus ostreatus use polycistron trna crispr guid rna strategi white rot fungus pleurotus ostreatus agaricomycet frequent use molecular genet studi mani use tool applic fungus particular effici gene target use homolog recombin crisprca enabl introduct mutat gene interest function analysi multipl gene encod various lignocellulos degrad enzym predict present genom therefor analys multipl gene mutant requir elucid mechan under lignocellulos degrad p ostreatus convent tool generat multipl gene mutat p ostreatus labori time consum therefor effici practic method need studi introduc crisprca assist multipl gene mutat use polycistron trna crispr guid rna approach frequenc tripl gene mutat fci vp tetracistron trna sgrna contain four differ sgrnas target fci vp vp express increas tripl gene mutat vp vp vp tricistron trna sgrna express replacedmodul promot trna sequenc studi demonstr first time applic strategi induc multipl gene mutat p ostreatus transform experi
|
D017394;D020076
|
T123;T004;T114
|
36,302,133
|
rural trauma telementor pilot project given canada geograph dispers popul initi trauma care may occur rural site may manag patient trauma frequent thus telementor play life save role articl describ rural trauma telementor pilot program british columbia report result evalu strength weak
|
D004635;D017216
|
T058;T091
|
36,302,132
|
health care cost total knee arthroplasti satisfi dissatisfi patient evid suggest patient dissatisfi total knee arthroplasti tka link dissatisfact use health care resourc unknown object studi compar cost tka satisfi dissatisfi patient
|
D019645;D020370
|
T061;T047
|
36,302,131
|
graft surviv kidney transplant standard versus prolong kidney procur time kidney procur ice remov kidney locat retroperitoneum risk rewarm owe time taken retriev abdomin thorac organ may lead poorer outcom purpos studi evalu impact prolong kidney procur time pkp outcom kidney transplant perform queen elizabeth ii health scienc centr halifax nova scotia canada
|
D016030;D009927
|
T061;T073;T055;T033;T058
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.